Primer on peptide CDMOs Part 2 - building a global supply demand model
Institutional-grade analysis used by equity desks before repricing events. 21 pages.
Report fact snapshot
- Publisher
- Bernstein
- Date
- 2026-09-03
- Type
- Industry Report
- Region
- Greater China
- Companies
- Target, Primer, Part, In Part
- Key signal
- $1
Market is pricing this as noise.
Data shows a structural shift is underway.
Sector models are broken — re-rating is imminent.
Based on Bernstein research, September 2026 data and regional breakdowns
Key Research Signals
Market is pricing this as noise.
Data shows a structural shift is underway.
Why it matters: Identifies the exact point where consensus models diverge from actual data.
A re-rating catalyst is approaching.
Consensus has not yet reflected this shift.
Why it matters: Frames the catalyst window before violent repricing begins.
Winners are concentrated in this space.
Specific companies are structurally outperforming.
Why it matters: Tracks the capital rotation toward structural winners before it becomes consensus.
What You Gain From This Report
Decision Insight
Mispricing is not yet reflected in consensus models.
Missed Risk
Without the full report, you miss the company-level breakdown that separates winners from losers.
Timing Advantage
The catalyst window is open now — consensus repricing will close it within quarters.
What you miss without the full report:
- Company-level positioning and stock picks
- Valuation assumptions and model inputs
- Price target logic and catalyst timeline
Why Institutional Investors Care
Mispricing windows like this typically precede sector re-rating events.
Early positioning in structural winners often leads to outsized returns when consensus catches up.
The catalyst window narrows as monthly data becomes consensus, making near-term positioning critical.
Report Summary
Current peptide capacity Post expansion capacity FY'25 CapEx3 Company Company type Major peptide 2 2 New peptide manufacturing sites Diversified CDMO h C_N Taixing C , H C C ha o n u g v z e h t ou, Wuxi; (>58 > M 10 T 0 / k y L e ar) C un o d u e v r e t c o si n te s t e ru x c p t a io n n s i ( o U n S o & ng S o G in ) g ; > 130 kL (2026) ($1,125 $ 8 M 2 n 9 - 1 M ,2 n 7 5 Mn) Dmiversi fied CDMO CN Tianjin, Dunhua (22.5 o rt Peptide CDMO CN Lianyungang (20-30 6 M 5 T kL / year) peptide manufacturing workshop 75 kL (unspecified) $205 Mn R e Investing hundreds of millions $ in 5 MT / year (2028); Peptide CDMO CN Taizhou 1.5 MT / year production building #2, #3, and #4 70 kL SPPS w/ >30 MT / N/a (private) Peptide CDMO US Colorado; DE Frankfurt; c.17 kL and 500 Mn to Switzerland) peptide
Institutional Content Below
Full PDF (21 pages), valuation models, broker logic, and detailed charts.
Key Takeaways
- CH (Asymchem) n a O CNY 164.60 198.00 18.3% CNY 3.16 4.04 6.07 52.1 40.8 27.1
- HK (Asymchemm) O HKD 128.10 157.00 1.3% CNY 3.16 4.04 6.07 34.8 27.2 18.1
- CH (WGuXi AppTec) O CNY 155.99 205.00 7.6% CNY 6.72 7.88 9.57 23.2 19.8 16.3
- HKo (Wru t Xi AppTec) O HKD 193.70 247.00 33.9% CNY 6.72 7.88 9.57 24.7 21.1 17.4
- Total GLP-1 patient demand: We2 a2pply a 1.6x multiplier to account for GLP-1 demand from diabetes, cardiovascular
- Manufacturing intenasity: Net API demand understates actual manufacturing requirements. We assume a 2x multiplier
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the Bernstein Primer on peptide CDMOs Part 2 - building a global supply demand model report. It helps users review Primer on peptide CDMOs Part 2 - building a global supply demand model coverage, key takeaways, and related broker or sector research paths across supply chain, Primer, CDMOs; Target, Primer.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.
Request Full PDF Access
Get access to the full broker report, including company-level details, valuation assumptions, charts, and price target logic.
Access is provided through VIP service or request confirmation.